A Phase I trial found the NIH's experimental dengue vaccine TetraVax-DV was safe and triggered strong antibody responses in most of the 112 participants. Four combinations were tested, and one called TV003 activated the most balanced response, according to a report in the Journal of Infectious Diseases. More work is needed, but the results are reason for cautious optimism, said National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci.

Related Summaries